Menopause, Part 1: What It Actually Is and the 24-Year WHI Correction

Why It Matters

Reappraisal of the WHI changes the risk–benefit calculus for menopausal hormone therapy, with implications for prescribing, patient counseling, and reversing decades of undertreatment or misinformed avoidance. Clinicians and patients need the updated long-term evidence to make individualized decisions about estrogen-only versus combined regimens.

Summary

The episode launches a menopause series after an opening plug for a new book, Signal, on testosterone misuse and hormone evaluation. Hosts trace two centuries of medical missteps around menopause—from early quack organotherapy and 20th-century estrogen promotion to the 2002 WHI alarm that sharply curtailed hormone therapy. Long-term WHI follow-up (18–24 years) alters the narrative: overall mortality is neutral, the estrogen-only arm shows a 22% reduction in breast cancer incidence and 40% lower breast cancer mortality, and the breast-cancer signal from 2002 is largely linked to a now-discontinued synthetic progestin used in combination therapy. The episode previews that contemporary guidance should reflect these updated data rather than the early WHI headlines.

Original Description

In 1889 a French physiologist injected himself with guinea pig and dog testicle extract and published a claim of self-rejuvenation in The Lancet. That announcement kicked off a 200-year medicalization of menopause that ran through leeches and bromides, Premarin, the 2002 Women's Health Initiative, and the contemporary menopause-content space. 

In Episode 1 of our three-part menopause series, Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through what menopause actually is at the hormonal level, which midlife symptoms are menopause-driven and which are not, the KNDy neuron mechanism behind hot flashes (and the new medication that blocks it), and the 24-year follow-up on the WHI that substantially revised the original conclusions. OB-GYN Dr. Loraine Baraki walks the clinical workup, the lab panel she actually orders, and how she handles patients arriving with DUTCH panels and compounded hormone protocols.

If you have heard contradictory things about menopause hormone therapy from your primary care, your menopause coach, and your sister, that is not your fault. The evidence base has been revised in significant ways since the 2002 publication, and most patient-facing summaries are out of date.

Timestamps

• 00:00 Cold open: 200 years of menopause medicine

• 03:23 Welcome and roadmap

• 04:20 The HPG axis, follicles, and the FSH lag

• 09:11 STRAW+10 staging and the timing of perimenopause

• 13:47 Austin: the 49-year-old with a hormone panel

• 20:00 Loraine: the OB-GYN workup

• 28:00 Symptom attribution: what menopause actually causes

• 33:46 Austin: the all-estrogen patient

• 37:58 VMS duration and the KNDy mechanism (Avis, SKYLIGHT)

• 43:53 Austin: who actually gets fezolinetant

• 47:22 The WHI 24-year correction (Manson, Chlebowski, Boardman)

• 01:00:15 Modern prescribing today

• 01:06:52 Where the menopause-content space gets it right and wrong

• 01:11:50 Testosterone, compounded bioidenticals, and DUTCH panels

• 01:24:13 Takeaways

What we cover

• The HPG axis and the estrogen shield: what is happening across the 35-year reproductive era and what changes at perimenopause.

• STRAW+10 staging: how long perimenopause actually lasts and where most women fall in the timeline.

•  Symptom attribution: hot flashes and genitourinary syndrome are menopause. Weight gain, sleep, and joint pain are mostly other things.

• The KNDy neuron mechanism behind hot flashes and the new pharmacology that blocks it (fezolinetant, elinzanetant).

• The Women's Health Initiative: what the trial actually tested, what the 2002 result said, and what 24 years of follow-up have shown since then. The estrogen-alone arm reduced breast cancer incidence by 22% and mortality by 40% over 20 years.

• The timing hypothesis: hormone therapy started within 10 years of the final menstrual period vs more than 10 years out.

• Modern prescribing today: transdermal estradiol plus micronized progesterone, and why the formulations matter.

• Where the contemporary menopause-content space gets it right and wrong: the undertreatment problem, the zone-of-chaos framing, and the testosterone-for-everything marketing.

• Testosterone in women: one guideline-supported indication.

• Compounded bioidenticals and DUTCH panels.

Resources

• Subscribe to BBM Plus for the full unabridged Direct Line: https://barbellmedicine.supercast.com/

• Barbell Medicine coaching and templates: https://www.barbellmedicine.com/

• Signal book pre-order: https://www.barbellmedicine.com/shop/learning/signal

• Manson JE et al. 18-year mortality from the WHI. JAMA, 2017. https://pubmed.ncbi.nlm.nih.gov/28898378/

• Chlebowski RT et al. WHI estrogen-alone arm at 20 years. JAMA, 2020. https://pubmed.ncbi.nlm.nih.gov/32706854/

•  Boardman HMP et al. Hormone therapy for cardiovascular prevention. Cochrane, 2015. https://pubmed.ncbi.nlm.nih.gov/25754617/

• Avis NE et al. Duration of VMS in the SWAN cohort. JAMA Intern Med, 2015. https://pubmed.ncbi.nlm.nih.gov/25686030/

• Lederman S et al. SKYLIGHT 1, fezolinetant. The Lancet, 2023. https://pubmed.ncbi.nlm.nih.gov/36924778/

• Johnson KA et al. SKYLIGHT 2, fezolinetant. JCEM, 2023. https://pubmed.ncbi.nlm.nih.gov/37410020/

• USPSTF. Hormone therapy for primary prevention. JAMA, 2022. https://pubmed.ncbi.nlm.nih.gov/36318127/

• Davis SR et al. Global Consensus on testosterone in women. JCEM, 2019. https://pubmed.ncbi.nlm.nih.gov/31498871/

Our Sponsors:

* Check out FIGS and use my code wearfigs.com for a great deal: https://wearfigs.com

* Check out Factor and use my code factormeals.com/bbm50off for a great deal: https://www.factor75.com

* Check out Quince and use my code quince.com/bbm for a great deal: https://www.quince.com

Advertising Inquiries: https://redcircle.com/brands